Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Single-Arm Study of Anti-HER2 Antibody-Drug Conjugates in HER2-Positive Homogeneous and Heterogeneous Early Breast Cancer as Neoadjuvant Therapy

NCT07844018 is registered in ClinicalTrials.gov with Peking University People's Hospital as lead sponsor.

NCT NCT07844018
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07844018 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Single-Arm Study of Anti-HER2 Antibody-Drug Conjugates in HER2-Positive Homogeneous and Heterogeneous Early Breast Cancer as Neoadjuvant Therapy
Lead sponsor
Peking University People's Hospital
Phase
Phase 2
Overall status
Not yet recruiting
Start date
January 1, 2027
Completion date
June 30, 2029
Enrollment
88 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer (early breast cancer)